Viking Therapeutics Inc VKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VKTX is a good fit for your portfolio.
News
-
Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
-
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
-
Viking Therapeutics to Participate at Upcoming Investor Conferences
-
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
-
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
-
This weight-loss ETF has performed well in its -2-
-
Healthcare stocks fade as obesity-drug optimism fades
Trading Information
- Previous Close Price
- $50.47
- Day Range
- $50.25–52.30
- 52-Week Range
- $8.28–99.41
- Bid/Ask
- $51.30 / $51.61
- Market Cap
- $5.65 Bil
- Volume/Avg
- 1.5 Mil / 3.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 28
Comparables
Valuation
Metric
|
VKTX
|
CBAY
|
EWTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.05 | 12.65 | 3.39 |
Price/Sales | — | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VKTX
CBAY
EWTX
Financial Strength
Metric
|
VKTX
|
CBAY
|
EWTX
|
---|---|---|---|
Quick Ratio | 29.38 | 10.70 | 36.49 |
Current Ratio | 29.48 | 10.96 | 37.08 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
VKTX
CBAY
EWTX
Profitability
Metric
|
VKTX
|
CBAY
|
EWTX
|
---|---|---|---|
Return on Assets (Normalized) | −15.98% | −30.06% | −23.18% |
Return on Equity (Normalized) | −16.71% | −51.97% | −24.45% |
Return on Invested Capital (Normalized) | −21.42% | −30.87% | −28.92% |
Return on Assets
VKTX
CBAY
EWTX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Ddbzbxwsg | Kwc | $628.7 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Ltfqgtk | Xgdcrbt | $121.4 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Pcrlllh | Whgrw | $114.0 Bil | |||
Moderna Inc
MRNA
| Dxlwpjsp | Zdlw | $45.3 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Xhfdsgmw | Cvwcdy | $31.5 Bil | |||
argenx SE ADR
ARGX
| Gxfrhkkh | Vzzn | $25.9 Bil | |||
BioNTech SE ADR
BNTX
| Crqzwgpfh | Hwl | $19.2 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Gnlpmxjp | Smcdw | $15.4 Bil | |||
United Therapeutics Corp
UTHR
| Pdrwnmcv | Gzr | $14.0 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Httbcfpcm | Gshddw | $11.7 Bil |